Organon & Co., headquartered in Jersey City, develops innovative health solutions in women’s health, biosimilars, and established brands, employing 10,000 people and operating six manufacturing facilities worldwide. The company went public on May 14, 2021, and offers products like Nexplanon and Follistim AQ through various distribution channels.
Matthew M Walsh bought 11,400 shares of OGN on 5 May at $8.82 per share, worth a total of $101K. They now own 144,484 OGN shares, or a 9% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
